Profile data is unavailable for this security.
About the company
Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).
- Revenue in CAD (TTM)0.00
- Net income in CAD-5.65m
- Incorporated2008
- Employees9.00
- LocationHelix Biopharma Corp401 Bay Street,, Suite 2704,PO Box 4TORONTO M5H 2Y4CanadaCAN
- Phone+1 (905) 841-2300
- Fax+1 (905) 841-2244
- Websitehttps://www.helixbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eastwood Bio-Medical Canada Inc | 736.75k | -531.60k | 37.86m | -- | -- | -- | -- | 51.39 | -0.0077 | -0.0077 | 0.0107 | -0.013 | 1.63 | -- | 38.65 | -- | -117.75 | -52.23 | -- | -140.29 | 60.00 | 52.09 | -72.15 | -52.90 | -- | -227.16 | -- | -- | -33.22 | 3.13 | -264.69 | -- | -- | -- |
| Medexus Pharmaceuticals Inc | 157.64m | 8.01m | 39.14m | 98.00 | 4.41 | 0.9727 | 2.45 | 0.2483 | 0.3629 | 0.3629 | 7.25 | 1.65 | 0.7547 | 2.19 | 5.44 | 1,608,578.00 | 3.83 | -6.83 | 8.44 | -9.79 | 52.91 | 53.90 | 5.08 | -11.45 | 0.7013 | 0.9426 | 0.6388 | -- | 40.93 | 69.17 | 142.41 | -- | -8.59 | -- |
| Charlotte's Web Holdings Inc | 79.37m | -41.57m | 39.34m | 164.00 | -- | 0.6189 | -- | 0.4957 | -0.271 | -0.271 | 0.517 | 0.4043 | 0.3668 | 1.07 | 27.08 | 483,988.00 | -19.21 | -25.71 | -22.16 | -29.03 | 55.88 | 48.98 | -52.37 | -63.11 | 2.33 | -- | 0.478 | -- | -14.82 | -1.90 | 59.88 | -- | -7.88 | -- |
| Immunoprecise Antibodies Ltd | 23.68m | -14.27m | 41.95m | 102.00 | -- | 0.8419 | -- | 1.77 | -0.4156 | -0.4156 | 0.6889 | 1.39 | 0.2939 | 5.25 | 6.76 | 170,420.70 | -17.70 | -23.62 | -19.62 | -27.25 | 51.88 | 57.18 | -60.23 | -76.18 | 1.38 | -- | 0.2241 | -- | 6.72 | 30.59 | -58.96 | -- | 34.04 | -- |
| IntelGenx Technologies Corp. | 1.43m | -15.03m | 41.96m | 48.00 | -- | -- | -- | 29.31 | -0.086 | -0.086 | 0.0082 | -0.1198 | 0.1245 | 14.36 | 1.74 | -- | -130.62 | -75.15 | -- | -133.79 | -66.03 | -- | -1,049.48 | -819.85 | 0.1153 | -4.88 | 23.66 | -- | 9.37 | -10.65 | 7.14 | -- | -30.32 | -- |
| Decibel Cannabis Company Inc | 115.96m | -1.77m | 44.96m | -- | -- | 0.974 | 33.56 | 0.3878 | -0.0045 | -0.0045 | 0.2739 | 0.1129 | 0.817 | 1.51 | 7.66 | -- | -1.25 | -3.55 | -2.04 | -5.19 | 36.10 | 38.83 | -1.53 | -7.13 | 0.3685 | 1.21 | 0.5122 | -- | 46.18 | -- | 60.33 | -- | -32.45 | -- |
| Microbix Biosystems Inc | 23.84m | 4.06m | 45.32m | 69.00 | 11.16 | 1.63 | 8.30 | 1.90 | 0.0296 | 0.0296 | 0.173 | 0.202 | 0.6703 | 1.67 | 6.33 | -- | 11.42 | -0.9729 | 12.72 | -1.17 | 54.38 | 52.30 | 17.04 | -1.55 | 4.98 | 3.53 | 0.1948 | -- | -13.43 | 5.71 | -102.21 | -- | -3.56 | -- |
| Helix Biopharma Corp. | 0.00 | -5.65m | 48.15m | 9.00 | -- | -- | -- | -- | -0.0277 | -0.0277 | 0.00 | -0.0012 | 0.00 | -- | -- | 0.00 | -318.95 | -261.49 | -574.76 | -- | -- | -- | -- | -- | -- | -2,825.00 | -- | -- | -- | -- | 4.16 | -- | -28.36 | -- |
| MustGrow Biologics Corp | 4.71m | -676.95k | 51.12m | 0.00 | -- | 9.49 | -- | 10.85 | -0.0144 | -0.0144 | 0.0944 | 0.1085 | 0.6697 | -- | 51.61 | -- | -9.62 | -50.41 | -11.96 | -59.28 | -- | -- | -14.37 | -298.73 | -- | -- | 0.1197 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -21.13m | 52.98m | 12.00 | -- | 1.54 | -- | -- | -0.1718 | -0.1718 | 0.00 | 0.3059 | 0.00 | -- | -- | 0.00 | -93.29 | -107.22 | -109.86 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
| LSL Pharma Group Inc | 10.03m | -8.47m | 53.00m | -- | -- | 4.67 | -- | 5.29 | -0.1117 | -0.1117 | 0.1264 | 0.105 | -- | -- | -- | -- | -- | -- | -- | -- | 16.40 | -- | -84.48 | -- | 0.2053 | -1.14 | 0.6527 | -- | -- | -- | -- | -- | -- | -- |
